TechnoPhage, SA - From science to innovative biopharmaceuticals
Title: Engineered Rabbit Antibody Variable Domains and Uses Thereof Office: Australia Patents Office Date: 16/10/2007 Patent no: 2008246442
TECHNOPHAGE, a biotechnology company headquartered in Lisbon, Portugal, announced today that the company has received authorization from U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for TP-102, a bacteriophage cocktail for the treatment of infected chronic ulcers, namely diabetic foot infections. This clearance will enable TechnoPhage to initiate…
New patent granted to TechnoPhage: Title: Antibacterial Phage, Phage Peptides and Methods Of Use Thereof Office: The Registry of Patents Singapore Date: 17/7/2014 Patent no: 173533
TECHNOPHAGE and SIMM, SHANGHAI INSTITUTE OF MATERIA MEDICA, a state-owned Institute administered and existing under the laws of the People’s Republic of China, have signed today a collaboration agreement for the joint development of a new pharmaceutical drug, leveraging the know-how and scientific complementarities of both entities in order to exploit new opportunities…

2019 events

18th Fraunhofer Seminar "Models of Lung Disease"
Hannover, Germany. January 24 - 25, 2019

Phage Futures Congress
Washington DC. January 29-30, 2019

Bacteriophage Therapy Summit
Boston, MA. March 26-27, 2019

29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Amsterdam, Netherlands. April 13-16, 2019